Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30259906 | 0.83 | RIPK1 (0.62) | CA12CA1CA2CA9RIPK1 | |
| SCHEMBL2905338 | 0.83 | RIPK1 (0.62) | CA12CA1CA2CA9RIPK1 | |
| SCHEMBL29686650 | 0.83 | MTNR1A (0.61) | TAAR1MTNR1AMTNR1B | |
| SCHEMBL533866 | 0.83 | MTNR1A (0.61) | TAAR1MTNR1AMTNR1B | |
| SCHEMBL33532174 | 0.83 | SPR (0.52) | TAAR1MTNR1AMTNR1BCA12CA1 | |
| SCHEMBL27586477 | 0.81 | MTNR1A (0.52) | MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL14242720 | 0.81 | TP53 (0.52) | MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL3638162 | 0.81 | TAAR1 (0.56) | TAAR1MTNR1AMTNR1BCA12CA1 | |
| SCHEMBL555438 | 0.80 | ALDH1A1 (0.49) | TAAR1MTNR1AMTNR1BCA12CA1 | |
| SCHEMBL14241867 | 0.80 | TAAR1 (0.56) | TAAR1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | TAAR1 1518/4885MTNR1A 3557/4885MTNR1B 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.